In recent years, the management strategy for type 2 diabetes mellitus (T2DM) has shifted from a glucocentric approach toward comprehensive management of multiple risk factors, particularly in the context of widely adopted novel pharmacological agents such as SGLT2 inhibitors and GLP-1 receptor agonists (56). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.